2013 annual shareholder meeting dwight babcock, ceo

2013 Annual Shareholder Meeting

Dwight Babcock, CEO

Fred Swindler Bill Cavanagh

Brien Ragle Krista Cline

Dale Boyce Clay O’Laughlin

Brachytherapy

External Beam

Robotic Surgery

Proton Beam

Task Force Report

Gliobastoma Brain Cancer Metastatic Brain Cancer Meningioma Brain Tumors Head and Neck Cancer Non Small Cell Lung Cancer Gynecologic Cancer

Prostate – Consolidation of I-125 & P-103 Brain Cancers and Tumors – None GliaSite Balloon Radiation Therapy – None Lung Cancer – I-125 sutured seeds No Mesh Gynecologic Cancer - None

*Published Papers Are Needed Prior To General Adoption

Pharma Model

Product development and pre-human testing: 5 years

Human Clinical Trials: 5 years

FDA Approval: 2 years

Adoption

IsoRay Prostate Model

Product development 510(k) FDA Approval 1-2 years

Early Adopters DataPublished Papers

5-6 years

Wider Scale Adoption

IsoRay New Product ModelProduct development 510(k) FDA Approval

1-2 years

Early Adopters DataPublished Papers

1-3 years

Wider Scale Adoption

Cornell Weill – Lung Cancer Cornell Weill – Metastatic Brain Cancer Archibold Medical – Lung Cancer MD Anderson – Intermediate Prostate

Cancer Sylvestor – Dual Therapy Prostate Cancer Cole – Mono Therapy Prostate Cancer Barrows – Meningioma Brain Tumors